Dr. Miron on impact of upfront chemo choice on second-line immunotherapy in bladder cancer
First study author Benjamin Miron, MD, a second-year hematology/oncology fellow at Fox Chase Cancer Center, discusses a study of real-world data that explored the influence of first-line chemotherapy choice on overall survival (OS) outcomes in patients with advanced urothelial carcinoma who received immunotherapy in the second-line setting.
Miron et al specifically compared the choice between frontline cisplatin plus gemcitabine versus frontline carboplatin plus gemcitabine. Although there was a numerical benefit favoring cisplatin, the results showed that the specific choice of frontline platinum therapy did not result in a significant difference in OS in patients subsequently receiving second-line immunotherapy.
The results were shared during the 2021 ASCO Annual Meeting (J Clin Oncol 39, 2021 [suppl 15; abstr 4535]. doi:10.1200/JCO.2021.39.15_suppl.4535). Miron conducted the study with other Fox Chase colleagues, including Elizabeth Handorf, PhD, an associate professor in the Cancer Prevention and Control Program, and Daniel M. Geynisman, MD, an associate professor in the Department of Hematology/Oncology.
Lenvatinib/pembrolizumab compares favorably with frontline standards in renal cell carcinoma
February 2nd 2024“Combination therapy with lenvatinib plus pembrolizumab provides a comparable OS, and a trend of improvement in PFS and response outcomes, compared with most current global SOC therapies for treatment-naïve patients with advanced renal cell carcinoma,” the study authors wrote.
First-line pembrolizumab/lenvatinib shows efficacy for advanced non–clear cell RCC
January 29th 2024“Updated efficacy and safety results continue to support pembrolizumab plus lenvatinib as a first-line treatment option for patients with advanced non–clear cell RCC,” lead study author Martin H. Voss, MD.
